There’s an interesting subtext to pharmaceutical companies’ battle against COVID-19. Taming the “invisible enemy” is undoubtedly the main objective, but the race for a vaccine or treatment has also created a David vs. Goliath narrative between the companies chasing solutions.July 1 provided a good example of this subtle duel.Pharma giant Pfizer and its partner, BioNTech, presented the first set of positive data from a Phase 1/2 study of their experimental coronavirus vaccine.All 24 participants who received two doses (of either 10 or 30 micrograms) of its BNT162b1 candidate produced neutralizing antibodiesseven days after the second dose.As a result, shares of …read more
Source:: Yahoo Finance
